Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 41
Filter
Add more filters

Complementary Medicines
Publication year range
1.
Afr Health Sci ; 23(2): 179-185, 2023 Jun.
Article in English | MEDLINE | ID: mdl-38223622

ABSTRACT

Background: To analyse the correlation between vaginal flora and cervical immune function of HPV-infected patients with cervical cancer. Methods: Six hundred females with genital tract infections treated in Xuzhou Hospital of Traditional Chinese Medicine from January 2014 to December 2016 were selected and divided into a high-risk HPV group (n=246) and a control group (n=354). The vaginal flora and human T lymphocyte subsets (CD3+, CD4+, CD8+) were detected. Multivariate logistic regression analysis was performed to explore the risk factors for HPV infection. Results: The numbers of CD4+ and CD4+/CD8+ T cells of the high-risk HPV group were significantly lower than those of the control group (P<0.05). The two groups had similar numbers of CD3+ and CD8+ T cells. In the high-risk HPV group, the positive rates of Lactobacillus, Chlamydia trachomatis, Mycoplasma hominis, mycetes, Ureaplasma urealyticum and bacterial vaginosis were significantly higher than those of the control group (P<0.05). There was no significant difference in the positive rates of trichomonads between the two groups. Multivariate logistic regression analysis revealed that C. trachomatis and U. urealyticum were independent risk factors for high-risk HPV infection (P<0.05). Conclusion: High-risk HPV infection in patients with cervical cancer was associated with vaginal flora and immune function. C. trachomatis and U. urealyticum were independent risk factors for high-risk HPV infection.


Subject(s)
Chlamydia Infections , Papillomavirus Infections , Uterine Cervical Neoplasms , Female , Humans , Uterine Cervical Neoplasms/complications , Papillomavirus Infections/complications , Human Papillomavirus Viruses , Chlamydia Infections/complications , Chlamydia Infections/microbiology , Immunity , Chlamydia trachomatis
2.
Vet Microbiol ; 217: 90-96, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29615263

ABSTRACT

Lamydia pecorum is a globally recognised livestock pathogen that is capable of causing severe and economically significant diseases such as arthritis in sheep and cattle. Relatively little information is available on the clinical progression of disease and the long-term effects of asymptomatic and symptomatic chlamydiosis in sheep. Recent studies in calves indicate that endemic C. pecorum infections may reduce growth rates. To investigate the clinical health parameters and production impacts of endemic C. pecorum infection in an Australian commercial lamb flock, we performed bimonthly sampling and clinical health assessments on 105 Border Leicester lambs from two to ten months of age. Chlamydial status was investigated via serology and species-specific quantitative PCR. Throughout the study period, conjunctivitis remained a persistent clinical feature while signs of arthritis (e.g. palpable synovial joint effusions) resolved in a subset of lambs while persisting in others. Clinical disease and C. pecorum infection were highest at six months of age (weaning). As previously reported, peak seroconversion tends to occur two months after the onset of clinical symptoms (6 months of age), with lambs clearing chlamydial infection by 10 months of age, despite ongoing disease still being present at this time. Notably, the presence of chlamydial infection did not affect lamb mass or growth rates throughout the study. At necropsy, C. pecorum was not detected within the joints of lambs with chronic arthritis. Molecular analysis of the strains in this flock suggest that the infecting strains circulating in this flock are clonal C. pecorum pathotypes, denoted ST 23, commonly associated with conjunctivitis and polyarthritis in Australian sheep. This study provides a platform for further research in the epidemiology and disease transmission dynamics of C. pecorum infections in sheep.


Subject(s)
Chlamydia Infections/veterinary , Chlamydia/isolation & purification , Endemic Diseases/veterinary , Sheep Diseases/epidemiology , Animals , Arthritis/microbiology , Australia/epidemiology , Chlamydia/genetics , Chlamydia/pathogenicity , Chlamydia Infections/complications , Chlamydia Infections/microbiology , Chlamydia Infections/physiopathology , Conjunctivitis/microbiology , Farms , Livestock/microbiology , Real-Time Polymerase Chain Reaction , Sheep/microbiology , Sheep Diseases/microbiology , Sheep Diseases/transmission , Sheep, Domestic/growth & development , Sheep, Domestic/microbiology , Species Specificity
4.
Vestn Otorinolaringol ; 81(4): 60-63, 2016.
Article in Russian | MEDLINE | ID: mdl-27500582

ABSTRACT

The present study included 201 adult patients presenting with exacerbation of chronic maxillary sinusitis. The presence of Chlamydia trachomatis and Chl. pneumoniae was verified by the direct immunofluorescencetechnique and polymerase chain reaction. The study material consisted of swipes und swabs from the mucous membrane of the middle nasal passage. The information from the patients was collected with the use of a questionnaire specially elaborated for the purpose of this study. The correlation relationships were established by means of gamma-statistics. The method is based on the calculation of the integral index characterizing the risk of development of chlamydial infection using the scoring scale for the evaluation of the clinical and anamnestic characteristics of the patients. The assessment of the risk of chlamydial colonization by the anamnestic method makes it possible to enhance the effectiveness of clinical diagnostics of chlamydial infection and thereby provides a basis for the prescription of the adequate anti-chlamydial treatment facilitating reduction of the frequency of complications and preventing dissemination of the causative factor of the disease. Moreover, this approach creates the conditions for the targeted selection of the patients to be referred to the laboratory verification of Chlamydia. Highoperating performance and effectiveness characteristics of the clinic-anamnestic diagnostics make it a method of choice for the wide application in the clinical practice.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Chlamydia Infections , Chlamydia trachomatis , Chlamydophila pneumoniae , Maxillary Sinusitis , Adult , Bacteriological Techniques/methods , Chlamydia Infections/complications , Chlamydia Infections/diagnosis , Chlamydia Infections/drug therapy , Chlamydia Infections/microbiology , Chlamydia trachomatis/drug effects , Chlamydia trachomatis/isolation & purification , Chlamydophila pneumoniae/drug effects , Female , Humans , Male , Maxillary Sinusitis/diagnosis , Maxillary Sinusitis/drug therapy , Maxillary Sinusitis/microbiology , Maxillary Sinusitis/physiopathology , Microbial Sensitivity Tests/methods , Middle Aged , Risk Assessment , Secondary Prevention , Treatment Outcome
5.
Urologiia ; (5): 103-108, 2016 Nov.
Article in Russian | MEDLINE | ID: mdl-28248030

ABSTRACT

To investigate the effectiveness of Ingaron (interferon-) in the treatment of HPV infection associated with sexually transmitted infections, the authors analyzed the scientific literature on the association of human papillomavirus infection with other viral and microbial pathogens. A clinical case of the association of human papillomavirus infection, urogenital infections (urogenital chlamydia and genital herpes) and localized scleroderma penis is described. The results of integrated therapy of diseases with the help of Interferon-gamma have been presented. According to the literature, up to 70-80% of HPV infections are associated with microbial (opportunistic, obligate pathogens) and viral infectious agents. Chronic inflammation caused by bacterial and viral associations destroys the immune system and it leads to the ineffectiveness of the therapy. Pathogenic therapy of sexually transmitted infections in combination with interferon-gamma (Ingaron) contributes to the eradication of bacterial pathogens, prevention of viral STI recurrence and elimination of high oncogenic risk types of HPV. Thus, we can reasonably infer that Ingaron (interferon-) alleviates the initial immune disturbances, improves the effectiveness of the treatment and may be recommended for treating HPV infection associated with sexually transmitted infections.


Subject(s)
Antiviral Agents/therapeutic use , Interferon-gamma/therapeutic use , Papillomavirus Infections/drug therapy , Sexually Transmitted Diseases, Viral/drug therapy , Adult , Chlamydia Infections/complications , Chlamydia Infections/drug therapy , Coinfection , Herpes Genitalis/complications , Herpes Genitalis/drug therapy , Humans , Male , Male Urogenital Diseases/complications , Male Urogenital Diseases/drug therapy , Scleroderma, Localized/complications , Scleroderma, Localized/drug therapy
6.
BMC Public Health ; 14: 704, 2014 Jul 09.
Article in English | MEDLINE | ID: mdl-25011479

ABSTRACT

BACKGROUND: Chlamydia trachomatis infections in pregnancy can cause maternal disease, adverse pregnancy outcomes and neonatal disease, which is why chlamydia screening during pregnancy has been advocated. The effectiveness of a screening program depends on the knowledge of health care professionals, women and partners and the acceptability for screening of the target population. We assessed the knowledge of chlamydia infection among pregnant women and their partners in the Netherlands, their attitudes towards testing, and their experiences of being offered a chlamydia test. In addition, we evaluated the association between participants' background characteristics and knowledge of chlamydia. METHODS: Pregnant women aged ≤ 30 years and their partners (regardless of their age) attending one of the participating primary midwifery care practices in the Netherlands were invited to participate. All participants completed a questionnaire, pregnant women provided a vaginal swab and partners provided a urine sample to test for C. trachomatis. RESULTS: In total, 383 pregnant women and 282 partners participated in the study of whom 1.9% women and 2.6% partners tested chlamydia positive. Participants had high levels of awareness (92.8%) of chlamydial infection. They were knowledgeable about the risk of chlamydia infection; median knowledge score was 9.0 out of 12.0. Lower knowledge scores were found among partners (p-value <0.001), younger aged (p-value 0.02), non-western origin (p-value <0.001), low educational level (p-value <0.001), and no history of sexually transmitted infections (p-value <0.001). In total, 78% of respondents indicated that when pregnant women are tested for chlamydia, their partners should also be tested; 54% believed that all women should routinely be tested. Pregnant women more often indicated than partners that testing partners for chlamydial infection was not necessary (p-value <0.001). The majority of pregnant women (56.2%) and partners (59.2%) felt satisfied by being offered the test during antenatal care. CONCLUSION: Pregnant women and their partners were knowledgeable about chlamydial infection, found testing, both pregnant women and their partners, for chlamydia acceptable and not stigmatizing.


Subject(s)
Awareness , Chlamydia Infections/diagnosis , Chlamydia trachomatis , Health Knowledge, Attitudes, Practice , Mass Screening , Patient Acceptance of Health Care , Pregnancy Complications, Infectious/diagnosis , Adolescent , Adult , Chlamydia Infections/complications , Chlamydia Infections/epidemiology , Chlamydia Infections/microbiology , Cross-Sectional Studies , Female , Humans , Male , Midwifery , Netherlands/epidemiology , Pregnancy , Pregnancy Complications, Infectious/epidemiology , Pregnancy Complications, Infectious/microbiology , Pregnancy Outcome , Prenatal Care , Prevalence , Sexual Partners , Sexually Transmitted Diseases/complications , Sexually Transmitted Diseases/diagnosis , Sexually Transmitted Diseases/epidemiology , Sexually Transmitted Diseases/microbiology , Surveys and Questionnaires , Young Adult
7.
Int J STD AIDS ; 24(3): 185-91, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23514834

ABSTRACT

Advances in technology have raised the possibility of including gonorrhoea testing as part of chlamydia screening. In England this is recommended only where the positive predictive value (PPV) of the test is ≥90%. This study assessed the PPV for gonorrhoea testing using routine testing data. Routine data (including gonorrhoea testing) from the Greater Manchester Chlamydia Screening Programme (GMCSP) in 2009/2010, were used to estimate the PPV for gonorrhoea testing. Of those screened, 0.3% (59/18044) of men and 0.4% (174/41873) of women tested positive for gonorrhoea. The PPV was 82.3% in women and 73.6% in men, in those who also tested positive for chlamydia. For women and men testing negative for chlamydia the PPV for a positive gonorrhoea test was incalculable. The low PPV observed in most groups suggests that where population testing for gonorrhoea occurs there is a need for further confirmatory testing of positive results before treatment decisions are made. Clinicians should be aware of screening test result limitations in this context.


Subject(s)
Chlamydia Infections/complications , Chlamydia trachomatis/isolation & purification , Gonorrhea/diagnosis , Mass Screening/methods , Neisseria gonorrhoeae/isolation & purification , Chlamydia Infections/diagnosis , Chlamydia Infections/epidemiology , England/epidemiology , False Negative Reactions , False Positive Reactions , Female , Gonorrhea/complications , Gonorrhea/epidemiology , Gonorrhea/therapy , Humans , Male , Mass Screening/statistics & numerical data , National Health Programs , Nucleic Acid Amplification Techniques , Predictive Value of Tests , Prevalence , Retrospective Studies , Sensitivity and Specificity , Sex Distribution
8.
Sex Transm Dis ; 39(1): 8-15, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22183837

ABSTRACT

BACKGROUND: In the Netherlands, no guidelines exist for routine sexually transmitted infection (STI) screening of human immunodeficiency virus (HIV)-infected men having sex with men (MSM). We assessed prevalence and factors associated with asymptomatic STI. METHODS: MSM visiting HIV outpatient clinics of academic hospitals were tested for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), syphilis, and hepatitis B and C infection. Prevalence and risk factors were studied using logistic regression. RESULTS: In total, 659 MSM were included between 2007 and 2008. STI were found in 16.0% of patients, mostly anal CT and syphilis. One new hepatitis B and 3 new hepatitis C infections were identified. In multivariate analyses, any STI (syphilis, CT, or NG) was associated with patient's age below 40 years (odds ratio [OR]: 2.5, 95% confidence interval [CI]: 1.3-5.0), having had sex with 2 or more sexual partners (OR 2.1, 95% CI: 1.2-3.5), the use of the same sexual toys with a sexual partner (OR 2.2, 95% CI: 1.0-4.9), and enema use before sex (OR: 2.3, 95% 1.2-4.2). Syphilis was independently associated with fisting with gloves versus no fisting (OR: 4.9, 95% CI: 1.7-13.7) and with rimming (OR: 5.0, 95% CI: 1.7-15.0). CT or NG were associated with age below 45 years (age 40-44 years: OR: 2.4, 95% CI: 1.1-5.3; age <40 years: OR: 2.4, 95% CI: 1.1-5.4), enema use before sex (OR: 2.4, 95% CI: 1.3-4.4) and drug use during sex (OR: 2.4, 95% CI: 1.4-4.0). CONCLUSIONS: High-risk sexual behavior was very common, and 16% of HIV-infected MSM in HIV care had an asymptomatic STI, mostly anal CT and syphilis. Development of STI screening guidelines is recommended.


Subject(s)
Chlamydia Infections/epidemiology , Chlamydia trachomatis/isolation & purification , HIV Infections/complications , Sexually Transmitted Diseases/epidemiology , Syphilis/epidemiology , Adult , Asymptomatic Diseases , Chlamydia Infections/complications , Chlamydia Infections/diagnosis , HIV Infections/epidemiology , Hepatitis B/complications , Hepatitis B/diagnosis , Hepatitis B/epidemiology , Hepatitis C/complications , Hepatitis C/diagnosis , Hepatitis C/epidemiology , Homosexuality, Male , Humans , Incidence , Logistic Models , Male , Middle Aged , Netherlands/epidemiology , Outpatients , Prevalence , Risk Factors , Sexual Behavior , Sexually Transmitted Diseases/complications , Sexually Transmitted Diseases/diagnosis , Syphilis/complications , Syphilis/diagnosis , Treponema pallidum/isolation & purification
10.
Urologiia ; (3): 31-6, 2008.
Article in Russian | MEDLINE | ID: mdl-18669345

ABSTRACT

Urogenital chlamydial monoinfection was diagnosed in 127 males using enzyme immunoassay, polymerase chain reaction, transrectal ultrasound examination of the prostatic gland. Of them, 72 patients had chronic urethroprostatitis. Microhemodynamics of these patients was studied with laser doppler flowmetry of the prostate and urethra. The patients received etiotropic therapy with fromilide, regional transurethral and transrectal ozone therapy. The symptoms relieved in 4-6 weeks. Repeated enzyme immunoassay and polymerase chain reaction stated elimination of the infective agent. Improvement of hemodynamics and urethral, prostatic microcirculation was stated after administration of regional ozone therapy.


Subject(s)
Chlamydia Infections/therapy , Male Urogenital Diseases/therapy , Oxidants, Photochemical/therapeutic use , Ozone/therapeutic use , Adult , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Chlamydia Infections/complications , Chlamydia Infections/diagnostic imaging , Chlamydia Infections/drug therapy , Combined Modality Therapy , Humans , Laser-Doppler Flowmetry , Male , Male Urogenital Diseases/complications , Male Urogenital Diseases/diagnostic imaging , Male Urogenital Diseases/drug therapy , Microcirculation/diagnostic imaging , Microcirculation/drug effects , Middle Aged , Oxidants, Photochemical/administration & dosage , Ozone/administration & dosage , Prostate/blood supply , Prostate/diagnostic imaging , Prostate/microbiology , Treatment Outcome , Ultrasonography , Urethra/blood supply , Urethra/diagnostic imaging , Urethra/microbiology
12.
Zhongguo Zhong Yao Za Zhi ; 32(6): 523-5, 2007 Mar.
Article in Chinese | MEDLINE | ID: mdl-17552161

ABSTRACT

OBJECTIVE: To study the effects of Salvia miltiorrhiza on treatment of Chlamydia trachomatis salpingitis (CTS) and fibrosis. METHOD: A mouse model for CTS was estahlished in C3H/He by intravaginal inoculation. after 3 weeks mice were randomly divided into 3 groups. Only Azithromyxin was given orally, Azithromyxin and early S. miltiorrhiza given, or Azithromyxin and later S. miltiorrhiza given. After 10 weeks, observe the change of oviduct of mice, observe the histopathologic change and analysis collagen histochemical index. RESULT: 3 Treatment groups induce tubal occlusion and hydrosalpinx decreased and the collagen histochemical index decreased significantly than those of no treatment given (P < 0.05). Early S. miltiorrhiza given group induce tubal occlusion and hydrosalpinx decreased and the collagen histochemical index decreased significantly than only Azithromyxin group or later S. miltiorrhiza given group (P <0.05). CONCLUSION: When we treat CTS genital infection with Azithromyxin, if we can give S. miltiorrhiza treatment as early as possible, it may decrease tubal occlusion and hydrosalpinx. significantly inhibit fibrosis maybe one of its pharmacologic mechanismin.


Subject(s)
Chlamydia Infections/drug therapy , Drugs, Chinese Herbal/therapeutic use , Salpingitis/drug therapy , Salvia miltiorrhiza/chemistry , Animals , Chlamydia Infections/complications , Chlamydia Infections/microbiology , Chlamydia trachomatis/drug effects , Drugs, Chinese Herbal/isolation & purification , Fallopian Tube Diseases/etiology , Fallopian Tube Diseases/prevention & control , Fallopian Tubes/drug effects , Fallopian Tubes/pathology , Female , Fibrosis , Mice , Mice, Inbred C3H , Phytotherapy , Plants, Medicinal/chemistry , Random Allocation , Salpingitis/complications
13.
Blood ; 108(5): 1451-60, 2006 Sep 01.
Article in English | MEDLINE | ID: mdl-16638927

ABSTRACT

The recent literature shows that interest in ocular adnexal lymphomas and their biologic and clinical characteristics--along with their possible association with Chlamydia psittaci infection and therapeutic management with rituximab or anti-Chlamydia psittaci antibiotic therapy--is considerable. These new data have modified the previously reported features of this disease and have made an updated review of the literature necessary. The aims of this review are to present the current knowledge on the biology of these lymphomas, their clinical features and prognostic factors, and the panel of all available treatment options.


Subject(s)
Eye Neoplasms/pathology , Eye Neoplasms/therapy , Lymphoma, B-Cell, Marginal Zone/pathology , Chlamydia Infections/complications , Eye Neoplasms/genetics , Eye Neoplasms/microbiology , Humans , Lymphoma, B-Cell, Marginal Zone/genetics , Lymphoma, B-Cell, Marginal Zone/microbiology , Lymphoma, B-Cell, Marginal Zone/therapy , Neoplasm Staging , Prognosis , Treatment Outcome
14.
Arch Pediatr ; 12 Suppl 1: S32-4, 2005 Apr.
Article in French | MEDLINE | ID: mdl-15893235

ABSTRACT

Incidence of chlamydial infection depends on maternal colonization during pregnancy, which is different in each population. The transmission is not obligatory but when present, it occurs at birth through the genital tractus. Chlamydia trachomatis infection is the first cause of neonatal conjunctivitis, with no influence of eye lotion application at birth. C. trachomatis is also responsible for interstitial pneumonia with possible consequences on the lung function. The laboratory diagnosis relies on the identification of intracellular bacteria in patient samples by the mean of culture or PCR. Systemic antibiotherapy by macrolides is always necessary, with local application in the case of conjunctivitis. The key point is the detection of colonization of pregnant women with identified risk factors. In positive case, oral treatment of both parents is recommended.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Chlamydia Infections/epidemiology , Chlamydia/pathogenicity , Conjunctivitis/etiology , Macrolides/therapeutic use , Adult , Chlamydia Infections/complications , Chlamydia Infections/drug therapy , DNA, Bacterial , Female , Humans , Incidence , Infant , Infant, Newborn , Infant, Newborn, Diseases , Infectious Disease Transmission, Vertical , Male , Polymerase Chain Reaction , Pregnancy , Risk Factors
15.
Med Hypotheses ; 63(4): 616-23, 2004.
Article in English | MEDLINE | ID: mdl-15325005

ABSTRACT

The present paper proposes a new therapy using Trypanosoma cruzi trans-sialidase to treat diseases with unclear pathogenesis that present in common chronic inflammation and fibrosis. This hypothesis is based on recent findings that co-infection with mycoplasma and chlamydia is present in many of these diseases and that this enzyme was capable to eliminate or decrease the co-infection from the host. We identified that mycoplasmas and chlamydias are present in atherosclerosis, aortic valve stenosis, dilated cardiomyopathy, chronic chagasic myocarditis and cancer. We hypothetized that mycoplasmal infection may induce immunodepression in the host, favoring proliferation of pre-existent chlamydial infection and that elimination of mycoplasma would lead to improvement of the immune system resistance and the control of chlamydial proliferation. Mycoplasma has a particular parasitic relationship with host cells, involving strong adherence of their membranes, making it extremely difficult to eradicate mycoplasmal infection from the host. A new therapeutic approach is suggested using one or more agents that prevent or inhibit the adherence of mycoplasma to host cell membranes by removing sialic acid residues and preventing oxidation of the cells. The use of a neuraminidase enzyme, particularly the T. cruzi trans-sialidase enzyme, associated with treatment using anti-oxidating agents is proposed. Preliminary experimental animal and laboratory tests showed good results. The proposal that trans-sialidase from T. cruzi is efficient in combating co-infection of mycoplasma and chlamydia is based, at least in part, on the observation that chagasic patients suffering from T. cruzi infection present less mycoplasma and chlamydia infection in their tissues. Also, a lower incidence of the diseases above described to be related to mycoplasma infection is observed in chagasic patients. It is also hypothesized that co-infection with mycoplasma and chlamydia may induce oxidation of the host cells. Anti-oxidants such as those present in plant extracts may also be used in the treatment. Other diseases such as chronic hepatitis, glomerulonephritis, Multiple Sclerosis, Alzheimer's Syndrome and idiopathic encephalitis are other examples of chronic diseases where mycoplasma and chlamydia might be present, as they have the characteristics of unknown etiology, persistent chronic inflammation and fibrosis.


Subject(s)
Chlamydia Infections/complications , Chlamydia Infections/drug therapy , Glycoproteins/administration & dosage , Inflammation/drug therapy , Inflammation/etiology , Mycoplasma Infections/complications , Mycoplasma Infections/drug therapy , Neuraminidase/administration & dosage , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Inflammatory Agents/administration & dosage , Chronic Disease , Disease Models, Animal , Evidence-Based Medicine/methods , Humans , Rats , Treatment Outcome
16.
Arthritis Res Ther ; 6(4): 155-8, 2004.
Article in English | MEDLINE | ID: mdl-15225359

ABSTRACT

Rheumatoid arthritis (RA) is a common human disease with a prevalence of about 1% in most parts of the world. At the time of symptom onset it is difficult to predict the severity of subsequent disease course. After 2 years joint erosions are seen in most patients, and most patients become clinically disabled within 20 years. A recent meeting at the Kennedy Institute of Rheumatology (Imperial College, London) brought together representatives from several European centres of excellence, to discuss research funded by the EU Framework 5 Quality of Life Programme. This research network combines gene and protein expression profiling with different animal models of RA to identify cells, genes and pathways contributing to arthritis initiation, progression and chronicity. The studies discussed highlight the reality that collaboration between different research groups is the basis of groundbreaking research and, it is hoped, eventual new therapies for RA.


Subject(s)
Arthritis, Rheumatoid/drug therapy , Arthritis/genetics , Disease Models, Animal , Genes/genetics , Angiogenesis Inhibitors/therapeutic use , Animals , Arthritis/enzymology , Arthritis/microbiology , Arthritis, Experimental/drug therapy , Arthritis, Experimental/etiology , Arthritis, Experimental/genetics , Borrelia burgdorferi/isolation & purification , Chlamydia Infections/complications , Chlamydia Infections/enzymology , Chlamydia trachomatis/enzymology , Chlamydia trachomatis/isolation & purification , Enterobacteriaceae/enzymology , Enterobacteriaceae/isolation & purification , Enterobacteriaceae Infections/complications , Enterobacteriaceae Infections/enzymology , European Union , Gene Expression Profiling/methods , Lyme Disease/complications , Mice , Mice, Inbred DBA , United Kingdom
17.
Vestn Oftalmol ; 117(5): 51-2, 2001.
Article in Russian | MEDLINE | ID: mdl-11765472

ABSTRACT

A new method for treating chlamydial conjunctivitis consists in injections of ciprofloxacine for intravenous injections, which is injected (1 ml) under the inferior vault of the conjunctiva on novocaine pad (0.5 ml 0.5% solution) and intravenously by drip infusion (99 ml) twice daily for 7-10 days. The treatment led to clinical cure in all patients, no relapses were observed. This method ensures a high therapeutic effect and accelerates the recovery of patients with chlamydial conjunctivitis by 4.6 days. The method is recommended for patients with complicated forms of chlamydial conjunctivitis in severe and protracted cases with concomitant urogenital chlamydial infection and concomitant chronic gastrointestinal diseases, when oral antibiotic therapy is undesirable or precluded.


Subject(s)
Anti-Infective Agents/therapeutic use , Chlamydia Infections/drug therapy , Ciprofloxacin/therapeutic use , Conjunctivitis, Bacterial/drug therapy , Anti-Infective Agents/administration & dosage , Chlamydia Infections/complications , Ciprofloxacin/administration & dosage , Conjunctivitis, Bacterial/complications , Female , Humans , Infusions, Intravenous , Middle Aged , Time Factors
18.
QJM ; 93(6): 375-83, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10873188

ABSTRACT

We have developed a previously published paradigm concerning causation of coronary heart disease, based on the probability that the fundamental cause is a microbe, probably Chlamydia pneumoniae, and that the progress of the disease is influenced by number of accelerating and inhibiting factors. We propose that cigarette smoking acts via respiratory infection, this itself being influenced by immunocompetence resulting from sunlight exposure. We also propose an immuno-enhancing effect of oestrogen and an anti-inflammatory effect of statin therapy. In respect of the geographical variation of coronary heart disease, we emphasize that this must be viewed as part of the bigger picture of a high mortality from all causes in countries of North-west Europe that have a particularly low level of sunlight exposure. Finally, we draw attention to the Albanian, French, Italian, Northern Ireland and Scottish paradoxes which should lead to a major review of the conventional wisdom concerning the aetiogenesis of coronary heart disease.


Subject(s)
Chlamydia Infections/complications , Chlamydophila pneumoniae , Coronary Disease/etiology , Respiratory Tract Infections/complications , Altitude , Estrogens/immunology , Female , Humans , Hypolipidemic Agents/therapeutic use , Immunocompetence/physiology , Male , Sex Factors , Smoking/adverse effects , Social Class , Sunlight , Vitamin D Deficiency/complications
20.
Pediátrika (Madr.) ; 20(3): 113-118, mar. 2000. tab
Article in Es | IBECS | ID: ibc-12035

ABSTRACT

C. trachomatis es la bacteria más frecuentemente involucrada en la etiología de las enfermedades de transmisión sexual. En la mujer la cervicitis, que se puede complicar con endometritis, salpingitis e infertilidad, es la presentación clínica más común. Sin embargo, la mayoría de las infecciones genitales en la mujer son asintomáticas. En el hombre la uretritis y la epididimitis son formas frecuentes de presentación. El diagnóstico de las infecciones por C. trachomatis se puede hacer por métodos de detección de antígenos incluyendo la amplificación de los ácidos nucleicos. Dependiendo de la presentación clínica diversos protocolos de tratamiento se pueden implementar (AU)


Subject(s)
Adolescent , Adult , Female , Child, Preschool , Infant , Male , Child , Humans , Infant, Newborn , Genital Diseases, Male/diagnosis , Genital Diseases, Male/therapy , Genital Diseases, Female/diagnosis , Genital Diseases, Female/therapy , Endometritis/complications , Endometritis/diagnosis , Endometritis/therapy , Salpingitis/complications , Salpingitis/diagnosis , Salpingitis/therapy , Infertility/diagnosis , Infertility/etiology , Infertility/therapy , Urethritis/complications , Urethritis/diagnosis , Urethritis/therapy , Epididymitis/complications , Epididymitis/diagnosis , Epididymitis/therapy , Antigens , Nucleic Acids , Chlamydia trachomatis/isolation & purification , Chlamydia trachomatis/pathogenicity , Chlamydia Infections/complications , Chlamydia Infections/diagnosis , Chlamydia Infections/therapy , Chlamydia Infections/etiology , Azithromycin/therapeutic use , Amoxicillin/therapeutic use , Antibodies, Monoclonal , Uterine Cervicitis/complications , Uterine Cervicitis/diagnosis , Uterine Cervicitis/therapy , Sexually Transmitted Diseases/diagnosis , Sexually Transmitted Diseases/etiology , Sexually Transmitted Diseases/therapy , Cell Culture Techniques , Urethral Diseases/diagnosis , Urethral Diseases/etiology , Urethral Diseases/therapy , Salpingitis/complications , Salpingitis/diagnosis , Salpingitis/etiology , Salpingitis/therapy , Endometritis/diagnosis , Endometritis/etiology , Endometritis/therapy , Infertility/diagnosis , Infertility/etiology , Infertility/therapy , Pregnancy Complications/diagnosis , Pregnancy Complications/etiology , Chorioamnionitis/diagnosis , Chorioamnionitis/complications , Chorioamnionitis/therapy , Urethritis/complications , Urethritis/diagnosis , Urethritis/therapy , Epididymitis/complications , Epididymitis/diagnosis , Epididymitis/therapy , Prostatitis/complications , Prostatitis/diagnosis , Prostatitis/therapy , Conjunctivitis/diagnosis , Conjunctivitis/therapy , Otitis/diagnosis , Otitis/therapy , Pharyngitis/diagnosis , Pharyngitis/therapy , Proctitis/diagnosis , Proctitis/therapy , Clinical Laboratory Techniques , Uterine Cervicitis/diagnosis , Uterine Cervicitis/etiology , Uterine Cervicitis/therapy , Arthritis, Reactive/diagnosis , Arthritis, Reactive/therapy
SELECTION OF CITATIONS
SEARCH DETAIL